Novavax Inc. said on Friday, that they expect to provide a specific vaccine for the Omicron viruses in the fourth quarter of this year. It further added that the development of the shots for BA.4 and BA.5 subvariants is accelerated and will also have additional preclinical data on the Omicron subvariants in the late summer or fall.
The U.S. FDA on Thursday asked all “COVID-19” vaccine developers to update their shots and add components that protect from subvariants BA.4\5.
Earlier on the 1st of July, the NVAX stocks had increased by 9.5% higher, although its COVID-19 shots have yet to receive an emergency use approval in the US.
However, in Taiwan, the FDA has approved the emergency use of the drug Nuvaxovid (NVX-Co 2373) covid vaccine for those aged 18 and above.